[Sar9,Met(O2)11]-Substance P |
Catalog No.GC13610 |
NK1 tachykinin receptor agonist
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 110880-55-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | Rats initially receive an i.c.v. injection of artificial cerebrospinal fluid (aCSF; 1 μl) followed 60 min later by a single dose of either [Sar9,Met(O2)11]-Substance P (10 pmol (n=9), 25 pmol (n=9), 65 pmol (n=8) or 100 pmol (n=8)) or septide (10 pmol (n=12), 25 pmol (n=9), 65 pmol (n=6) or 100 pmol (n=6)) to construct a complete dose-response curve. Each rat is selected randomly and injected with only one of the two agonists for the remainder of the protocol. Increasing doses of [Sar9,Met(O2)11]-Substance P or septide are given at 24 h intervals on day 1 (10 pmol), day 2 (25 pmol), day 3 (65 pmol) and day 4 (100 pmol). Control rats (n=18) receive only the vehicle (aCSF) each day of experiment. Peptides are administered in a volume of 1 μL of vehicle followed by 5 μL flush volume of aCSF which corresponds to the void volume of the catheter. Each dose is calculated per rat in 1 μL solution[1]. |
References: [1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28. |
[Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist.
[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P is the sole to produce grooming[1].
Reference:
[1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28.
Cas No. | 110880-55-2 | SDF | |
Canonical SMILES | CC(C[C@@](/N=C(O)/CN(C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@]2([H])CCCN2C([C@](N)([H])CCCNC(N)=N)=O)([H])CCCCN)=O)([H])CCC(O)=N)([H])CCC(O)=N)([H])CC3=CC=CC=C3)([H])CC4=CC=CC=C4)=O)C)([H])/C(O)=N/[C@@](C(O)= | ||
Formula | C64H100N18O15S | M.Wt | 1393 |
Solubility | Soluble to 1 mg/ml in sterile water | Storage | Desiccate at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.7179 mL | 3.5894 mL | 7.1788 mL |
5 mM | 0.1436 mL | 0.7179 mL | 1.4358 mL |
10 mM | 0.0718 mL | 0.3589 mL | 0.7179 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 16 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *